Open AccessDie kliniese farmakologie van hirudien - 'n nuwe antistolmiddel
Author(s) -
B. H. Meyer,
F. O. Muller,
H. G. Luus,
Nathalie Rey
Publication year - 1992
Publication title -
suid-afrikaanse tydskrif vir natuurwetenskap en tegnologie/die suid-afrikaanse tydskrif vir natuurwetenskap en tegnologie
Language(s) - English
Resource type - Journals
eISSN - 2222-4173
pISSN - 0254-3486
DOI - 10.4102/satnt.v11i2.526
Subject(s) - hirudin , partial thromboplastin time , pharmacokinetics , pharmacology , plasma concentration , coagulation , medicine , chemistry , thrombin , platelet
Increasing doses of 0,05, 0,1, 0,15 and 0,2 mg/kg of rDNA hirudin, a new anti-coagulant, were given subcutaneously to 20 volunteers (5 per dose) in order to investigate the tolerance and pharmacokinetics of the compound and its effects on coagulation. Hirudin was tolerated very well, the elimination half-life after subcutaneous injections is about 2 hours, about 40% of a given dose is excreted through the kidneys, and an excellent linear relationship was found between the area under the plasma concentration time curve and the dose. Hirudin increased partial thromboplastin time in a dose-related fashion